We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+33.31%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.33B
AUM Growth
+$318M
Cap. Flow
-$111M
Cap. Flow %
-4.75%
Top 10 Hldgs %
67.66%
Holding
50
New
8
Increased
6
Reduced
18
Closed
5

Top Buys

Rank Stock Value
1
SPRB
Spruce Biosciences
SPRB
+$110M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$95M
3
ALGS icon
Aligos Therapeutics
ALGS
+$50.9M
4
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$37.2M
5
EAR
Eargo, Inc. Common Stock
EAR
+$31M

Top Sells

Rank Stock Value
1
VTI icon
Vanguard Morningstar Total Stock Market ETF
VTI
+$208M
2
MDT icon
Medtronic
MDT
+$103M
3
CTLT
CATALENT, INC.
CTLT
+$60.9M
4
AAPL icon
Apple
AAPL
+$25.8M
5
SIBN icon
SI-BONE Inc
SIBN
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 65.57%
2 Technology 5.9%
3 Financials 5.43%
4 Communication Services 5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNST
26
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$17.3M 0.74%
598,951
+20,817
+4% +$524K
MIST icon
27
Milestone Pharmaceuticals
MIST
$152M
$17M 0.73%
2,530,585
+450,000
+22% +$3.01M
FLXN
28
DELISTED
Flexion Therapeutics, Inc.
FLXN
$16.2M 0.69%
1,403,370
– –
INSM icon
29
Insmed
INSM
$28.6B
$14.3M 0.61%
430,107
– –
LUNG icon
30
Pulmonx
LUNG
$87.6M
$12.9M 0.55%
+187,047
New +$9.16M
KNTE
31
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$11.9M 0.51%
+300,000
New +$12M
XENT
32
DELISTED
Intersect ENT, Inc
XENT
$11.5M 0.49%
502,225
-11,290
-2% -$215K
SPRO icon
33
Spero Therapeutics
SPRO
$73M
$11.2M 0.48%
576,702
-354,397
-38% -$5.52M
PCVX icon
34
Vaxcyte
PCVX
$8.64B
$11.1M 0.47%
416,937
-234,318
-36% -$8.71M
AERI
35
DELISTED
Aerie Pharmaceuticals
AERI
$10.9M 0.47%
807,656
– –
AKUS
36
DELISTED
Akouos Inc
AKUS
$9.11M 0.39%
459,290
+684
+0.1% +$13.3K
INSP icon
37
Inspire Medical Systems
INSP
$1.74B
$7.52M 0.32%
40,000
-19,645
-33% -$3.21M
AFIB
38
DELISTED
Acutus Medical Inc
AFIB
$7.35M 0.32%
255,000
– –
BHVN
39
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$7.12M 0.31%
83,100
-1,500
-2% -$127K
ZGNX
40
DELISTED
Zogenix, Inc.
ZGNX
$6.51M 0.28%
325,814
– –
NARI
41
DELISTED
Inari Medical, Inc. Common Stock
NARI
$6.3M 0.27%
72,212
-3,288
-4% -$232K
SILK
42
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$5.04M 0.22%
80,102
-45,326
-36% -$2.81M
CRNX icon
43
Crinetics Pharmaceuticals
CRNX
$8.92B
$3.83M 0.16%
271,378
– –
CRVS icon
44
Corvus Pharmaceuticals
CRVS
$1.17B
$3.02M 0.13%
847,906
-541,592
-39% -$2.18M
FSTX
45
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$344K 0.01%
+34,819
New +$228K
AKBA icon
46
Akebia Therapeutics
AKBA
$252M
– –
-1,987,506
Closed -$4.99M
CVAC
47
DELISTED
CureVac
CVAC
– –
-201,642
Closed -$9.39M
MDT icon
48
Medtronic
MDT
$112B
– –
-988,136
Closed -$103M
SIBN icon
49
SI-BONE Inc
SIBN
$834M
– –
-698,504
Closed -$16.6M
ETTX
50
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
– –
-1,153,911
Closed -$2.35M
1
2

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q4 2020 Portfolio in Review

As of Q4 2020, Novo Holdings A/S held 50 positions worth $2.33B, up 16% from $2.01B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Novo Holdings A/S withdrew a net $111M in Q4 2020, closing 5 positions and reducing 18 holdings. Its most notable exit was Medtronic, an estimated $103M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 54% a quarter earlier, followed by Technology and Financials.

Against the trend, Novo Holdings A/S opened a new position in Spruce Biosciences worth $121M.

  • Novo Holdings A/S's largest Q4 2020 buy was Spruce Biosciences: 66,524 shares worth $121M.
  • Novo Holdings A/S added most to Freeline Therapeutics Holdings plc American Depositary Shares in Q4 2020, an estimated $28.4M increase.
  • Novo Holdings A/S's biggest Q4 2020 reduction was Vanguard Morningstar Total Stock Market ETF, cutting an estimated $208M.
  • Novo Holdings A/S fully exited Medtronic in Q4 2020, selling an estimated $103M.
  • Novo Holdings A/S's ten largest holdings make up 68% of its $2.33B portfolio in Q4 2020.
  • Novo Holdings A/S opened 8 new positions and closed 5 in Q4 2020.
  • Novo Holdings A/S's portfolio value rose 16% quarter-over-quarter to $2.33B.

Based on Novo Holdings A/S's 13F filing for Q4 2020, filed 16 Feb 2021.